ClinicalTrials.gg
Enrolling by invitationNCT07561359HSPMOVEUpdated May 1, 2026

12-Week Strength and Functional Exercise Program for Hereditary Spastic Paraplegia Trial (HSPMOVE)

An interventional study of Individualized Functional and Strength Exercises in Hereditary Spastic Paraplegia, sponsored by Hospital de Clinicas de Porto Alegre. Enrolling by invitation at 1 site in Brazil. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2024, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Study summary

This study aims to evaluate whether a 12-week program of strength and functional exercises can improve movement and daily function in people with Hereditary Spastic Paraplegia (HSP). Participants will take part in supervised exercise sessions twice a week, delivered by videoconference, with guidance from a physiotherapist. The exercises will be tailored to each participant's abilities and goals and will focus on improving muscle strength, balance, and walking.

The study is a randomized crossover trial, meaning that all participants will experience both the exercise program and a comparison period without the intervention.

Eligible participants are individuals aged 16 to 70 years with a clinical or genetically confirmed diagnosis of HSP, who are able to walk independently (with or without assistive devices) and have stable treatment for spasticity.

Researchers will measure changes in walking ability, balance, muscle strength, and quality of life using clinical scales and functional tests. These include walking tests, mobility assessments, and questionnaires about daily activities and confidence in movement. To reduce bias, outcome assessments will be performed by an evaluator who is blinded to the participants' group allocation.

The results of this study will help determine whether a structured exercise program is safe, feasible, and effective for improving motor symptoms in people with HSP, and may support its use as part of routine care.

02

Conditions studied

  • Hereditary Spastic Paraplegia

Keywords

  • Hereditary spastic paraplegia
  • rehabilitation
  • exercise
  • Physical Therapy
03

In context

Spastic Paraplegia, Hereditary

51 studies on the registry are indexed under Spastic Paraplegia, Hereditary; 20 are open to participants now.

This study's planned enrollment of 20 is close to the median of 20 across 25 interventional studies indexed under Spastic Paraplegia, Hereditary.

Browse Spastic Paraplegia, Hereditary studies →

Lead sponsor

Hospital de Clinicas de Porto Alegre is the lead sponsor of 456 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of hereditary spastic paraplegia confirmed by genetic testing or clinical diagnosis with a positive family history
  • Age between 16 and 70 years
  • Independent ambulation, with or without assistive devices
  • Access to an electronic device (smartphone, tablet, or computer) with camera and internet connection
  • Stable therapeutic regimen for spasticity management (pharmacological and/or physiotherapy) for at least 6 months prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Presence of other neurological or systemic conditions causing additional motor impairment or musculoskeletal injury limiting movement
  • Inability to perform performance outcomes even with assistive devices
  • Planned or ongoing botulinum toxin injections or surgical interventions for spasticity reduction during the 12-week intervention period
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Individualized Functional and Strength Exercise Intervention

    Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist.

    Other: Individualized Functional and Strength Exercises

  • No intervention
    No Intervention

    No individualized prescription or real-time supervision will be provided during this phase. They will receive printed educational materials containing general guidance on performing strength and functional exercises.

Interventions

  • OtherIndividualized Functional and Strength Exercises

    Individualized functional and strength exercise intervention delivered via videoconference and supervised by a physiotherapist. Exercises are tailored according to Goal Attainment Scaling (GAS) and baseline physical activity level. The program consists of two sessions per week and follows key training principles (individuality, overload, adaptation, specificity, continuity, reversibility, and variability) with progressive loading. The intervention focuses on improving lower limb strength and functional mobility, particularly gait, and includes balance and gait training. Sessions are scheduled with 2-3 day intervals. Each exercise includes 1-3 sets of 8-15 repetitions, with 30-60 seconds rest between sets. Training intensity ranges from 40-60% of maximal strength for sedentary participants and 50-70% for physically active participants.

06

What researchers measure

Primary outcomes

  1. Spastic Paraplegia Rating Scale (SPRS)

    Clinician-reported outcome used to assess disease severity in hereditary spastic paraplegia (HSP). It consists of 13 items evaluating gait, lower limb strength and spasticity, joint contractures, pain, and bladder and bowel function. Total scores range from 0 to 52, with higher scores indicating greater disease severity.

    Time frame: Baseline, 12 and 24 weeks

  2. Timed Up and Go Test (TUG) - maximum walking speed

    Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at maximum walking speed. The time to complete the task is recorded.

    Time frame: Baseline, 12 and 24 weeks

  3. Goal Attainment Scaling (GAS)

    individualized patient reported outcome measure used to assess the extent to which patient-specific goals are achieved during the intervention. Each participant will define four main individualized goals at baseline. Goals and expected levels of performance are defined individually for each participant and scored on a 5-point scale ranging from -2 to +2. A score of 0 represents the expected level of achievement, positive scores (+1, +2) indicate better-than-expected outcomes, and negative scores (-1, -2) indicate less-than-expected outcomes.

    Time frame: Baseline, 12 and 24 weeks

Secondary outcomes

  1. 10-Meter Walk Test (10MWT) - self-selected walking speed

    Performance outcome in which participants will walk at a comfortable, self-selected pace over a 10-meter distance. A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone. Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.

    Time frame: Baseline, 12 and 24 weeks

  2. 10-Meter Walk Test (10MWT) - maximum walking speed

    Performance outcome in which participants will walk at maximum walking speed over a 10-meter distance. A flying start will be used, allowing 2 meters for acceleration and 2 meters for deceleration outside the timed zone. Walking speed (m/s) is calculated based on the time to complete the central 10-meter distance.

    Time frame: Baseline, 12 and 24 weeks

  3. Timed Up and Go (TUG) - self-selected walking speed

    Performance outcome in which participants are instructed to stand up from a seated position, walk 3 meters, turn around, walk back, and sit down at at a comfortable, self-selected pace . The time to complete the task is recorded.

    Time frame: Baseline, 12 and 24 weeks

  4. Falls Efficacy scale - International (Brazilian Portuguese)

    Patient-reported outcome used to assess concern about falling during daily activities in community-dwelling individuals. It consists of 16 items covering functional and participation activities (e.g., sitting/standing from a chair, climbing stairs). Each item is scored from 1 (not at all concerned) to 4 (very concerned), with total scores ranging from 16 to 64. Higher scores indicate greater concern about falling.

    Time frame: Baseline, 12 and 24 weeks

  5. 36-Item Short Form Health Survey (SF-36) - Brazillian Portuguese

    Generic, patient-reported outcome of health-related quality of life. It consists of 36 items covering multiple domains, including physical functioning, role limitations due to physical health, pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores range from 0 to 100, with higher scores indicating better overall health status.

    Time frame: Baseline, 12 and 24 weeks

  6. Medical Research Council (MRC) Muscle Strength Scale

    Clinician-reported outcome of muscle strength, graded from 0 (no contraction) to 5 (normal strength). Lower limb muscle groups assessed include hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors.

    Time frame: Baseline, 12 and 24 weeks

  7. Modified Ashworth Scale (MAS)

    Clinician-reported outcome used to assess resistance to passive movement and muscle tone. It is scored on a 5-point scale from 0 (normal muscle tone) to 4 (rigid in flexion or extension). In this study, it will be applied to the hip adductor and knee flexor muscles to assess lower limb spasticity.

    Time frame: Baseline, 12 and 24 weeks

  8. Patient Global Impression of Change (PGI-C)

    Patient-reported outcome measuring perceived overall improvement or worsening following the intervention. It is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the patient's global assessment of change.

    Time frame: Baseline, 12 and 24 weeks

Other outcomes

  1. Handheld Dynamometry (microFET2)

    Digital health technology in which muscle strength will be assessed using a handheld dynamometer (microFET2) to measure peak force output in lower limb muscle groups including hip flexors and extensors, hip abductors and adductors, knee flexors and extensors, and ankle dorsiflexors and plantarflexors. This provides an objective, quantitative measure of muscle strength (expressed in kgf) for comparison with clinical scales.

    Time frame: Baseline, 12 and 24 weeks

  2. Instrumented Gait Analysis (Opal Sensors System) - Timed Up and Go test

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Sit-to-stand, turning, and stand-to-sit times in seconds (1 decimal) will be recorded during and Timed Up and Go (TUG) test at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  3. Instrumented Gait Analysis (Opal Sensors System) - Cadence

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Cadence in steps/min will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  4. Instrumented Gait Analysis (Opal Sensors System) - Elevation Midswing, Lateral Step Variability, Circumduction

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Elevation Midswing, Lateral Step Variability, Circumduction in cm will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  5. Instrumented Gait Analysis (Opal Sensors System) - Gait Cycle Duration, Step Duration

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Gait Cycle Duration and Step Duration in seconds will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  6. Instrumented Gait Analysis (Opal Sensors System) - Gait Speed

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Gait Speed in m/s will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  7. Instrumented Gait Analysis (Opal Sensors System) - Stride Length

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Stride Length in meters will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  8. Instrumented Gait Analysis (Opal Sensors System) - Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM)

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Foot Strike Angle, Toe Off Angle, Toe Out Angle, Lumbar Coronal (RoM), Lumbar Sagittal (RoM), Lumbar Transverse (RoM), Trunk Coronal (RoM), Trunk Sagittal (RoM), Trunk Transverse (RoM) in ° degrees will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

  9. Instrumented Gait Analysis (Opal Sensors System) - Double Support, Single Limb Support, Stance, Swing, Terminal Double Support

    Digital health technology. Biomechanical gait analysis will be performed using a six-sensor wearable system (Opal, Clario) to capture kinematic and spatiotemporal gait parameters. Double Support, Single Limb Support, Stance, Swing, Terminal Double Support in Gait Cycle Time (%) will be recorded during the 10-Meter Walk Test (10MWT). Data will be collected at both self-selected and maximum walking speeds.

    Time frame: Baseline, 12 and 24 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Cubillos Arcila DM, Dariva Machado G, Martins VF, Leotti VB, Schule R, Peyre-Tartaruga LA, Saute JAM. Long-term progression of clinician-reported and gait performance outcomes in hereditary spastic paraplegias. Front Neurosci. 2023 Sep 22;17:1226479. doi: 10.3389/fnins.2023.1226479. eCollection 2023. PubMed 37811319 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
May 1, 2026
StartActual
Apr 27, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07561359
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Apr 27, 2024
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion